Head-To-Head Contrast: 10x Genomics (NASDAQ:TXG) vs. Healthcare Triangle (NASDAQ:HCTI)

10x Genomics (NASDAQ:TXG) and Healthcare Triangle (NASDAQ:HCTI) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

Institutional and Insider Ownership

84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 0.3% of Healthcare Triangle shares are owned by institutional investors. 8.8% of 10x Genomics shares are owned by company insiders. Comparatively, 0.1% of Healthcare Triangle shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares 10x Genomics and Healthcare Triangle”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$642.82 million	4.40	-$43.54 million	($0.17)	-131.12
Healthcare Triangle	$13.89 million	0.32	-$9.48 million	($2,604.79)	0.00

Healthcare Triangle has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Healthcare Triangle, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

10x Genomics has a beta of 2.05, suggesting that its share price is 105% more volatile than the S&P 500. Comparatively, Healthcare Triangle has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500.

Profitability

This table compares 10x Genomics and Healthcare Triangle’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
10x Genomics	-3.55%	-2.86%	-2.23%
Healthcare Triangle	-70.43%	-166.88%	-43.00%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for 10x Genomics and Healthcare Triangle, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	1	9	4	1	2.33
Healthcare Triangle	1	0	0	0	1.00

10x Genomics presently has a consensus target price of $23.17, indicating a potential upside of 3.93%. Given 10x Genomics’ stronger consensus rating and higher possible upside, research analysts clearly believe 10x Genomics is more favorable than Healthcare Triangle.

Summary

10x Genomics beats Healthcare Triangle on 13 of the 15 factors compared between the two stocks.

About 10x Genomics

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

About Healthcare Triangle

Healthcare Triangle, Inc., a healthcare information technology company, focuses on developing solutions in the sectors of cloud services, data science, and professional and managed services for the electronic health record, and healthcare and life sciences industry. It provides a suite of software, solutions, platforms, and services that enables healthcare and pharma organizations to deliver personalized healthcare, precision medicine, advances in drug discovery, development and efficacy, collaborative research and development, respond to evidence, and accelerate their digital transformation. The company’s software platforms include CloudEz, an enterprise multi-cloud transformation and management platform that enables customers to manage their cloud infrastructure in private, hybrid, and public cloud infrastructures; and DataEz, a cloud-based data analytics and data science platform for the data analytics and data science requirements of life sciences/pharmaceutical and healthcare provider organizations. It also provides Readabl.AI, a Software-as-a-Service solution that uses public cloud artificial intelligence and machine learning to recognize and extract healthcare information from documents, faxes, and narrative reports. In addition, the company offers cloud IT services; and healthcare IT services, such as electronic health records and software implementation, optimization, and extension to community partners, as well as application managed services, and backup and disaster recovery on public cloud. It primarily serves healthcare delivery organizations, healthcare insurance companies, pharmaceutical and life sciences, biotech companies, and medical device manufacturers. The company was incorporated in 2019 and is based in Pleasanton, California. Healthcare Triangle, Inc. is a subsidiary of SecureKloud Technologies, Inc.